Back

Siglec1 Facilitates Macrophage-Cd8+ T Cell Interactions And Correlates With Cancer Immunotherapy Response

Ibanez Molero, S.; Coccimiglio, M.; Olivia Springer, B.; Bowien de Ruiter, M.; Clayton, G.; Wijnen, S.; Blank, C.; Labots, M.; de Gruijl, T.; van Kooyk, Y.

2026-07-15 immunology
10.64898/2026.07.09.737484 bioRxiv
Show abstract

Antigen-presenting cell (APC) interactions with cytotoxic T cells are critical for anti-tumour immunity and response to immune checkpoint blockade (ICB), yet context-specific regulators in the tumour microenvironment remain not fully defined. Here we identify the lectin receptor SIGLEC1 as a key mediator of macrophage-T cell interactions in human melanoma. In a well-characterized patient cohort, SIGLEC1 was selectively upregulated in inflammatory macrophages physically associated with activated/exhausted CD8 T cells. Imaging and functional analyses revealed that SIGLEC1 accumulates at the macrophage-T cell interface and promotes cell clustering. SIGLEC1 ligands were enriched on activated T cells, and their blockade reduced cytotoxic cytokine production ex vivo. Single-cell (spatial) transcriptomics across independent ICB-treated melanoma cohorts showed that SIGLEC1 macrophages localize near CD8 T cells and are enriched in responders, where they also associate with T cells expressing activation/exhaustion markers. These findings define a SIGLEC1-dependent macrophage-T cell niche linked to effective immunotherapy.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.